{
    "pmcid": "8458290",
    "qa_pairs": {
        "How did the C5-trimer demonstrate therapeutic efficacy in the Syrian golden hamster model?": [
            "By significantly reducing viral load and associated pathological changes.",
            "By completely preventing infection in all treated hamsters.",
            "By enhancing the immune response to other respiratory viruses.",
            "By increasing the production of host antibodies against SARS-CoV-2."
        ],
        "What is the primary advantage of nanobodies for treating respiratory diseases like COVID-19?": [
            "Their small size and stability allow for respiratory administration.",
            "They can be easily modified to target multiple viruses simultaneously.",
            "They are derived from human antibodies, reducing immunogenicity.",
            "Their large size enhances their ability to block viral entry."
        ],
        "What potential does the study suggest for combinations of nanobodies targeting different epitopes?": [
            "Enhancing resilience against emerging variants.",
            "Reducing the cost of production.",
            "Increasing the speed of viral clearance.",
            "Decreasing the need for booster doses."
        ],
        "What was a notable finding regarding the binding affinity of C1 and F2 nanobodies?": [
            "They maintained their binding affinity across all tested variants.",
            "They showed increased affinity for the Beta variant.",
            "They lost binding affinity for the Alpha variant.",
            "They only bound effectively to the original SARS-CoV-2 strain."
        ],
        "Which nanobodies were found to overlap with the ACE2 binding site on the SARS-CoV-2 RBD?": [
            "C5 and H3",
            "C1 and F2",
            "C5 and C1",
            "H3 and F2"
        ]
    }
}